A study of the safety of CMA-676 [gemtuzumab ozogamicin] in treatment of elderly patients with acute myeloid leukemia (AML) in first relapse

Trial Profile

A study of the safety of CMA-676 [gemtuzumab ozogamicin] in treatment of elderly patients with acute myeloid leukemia (AML) in first relapse

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2005

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top